Amneal Pharmaceuticals, Inc.AMRXNASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank100
5Y CAGR+166.5%
Year-over-Year Change
Year-over-year operating income growth rate
5Y CAGR
+166.5%/yr
Long-term compound
Percentile
P100
Near historical high
vs 5Y Ago
134.4x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 97964.96% |
| Q3 2025 | -100.11% |
| Q2 2025 | 10.99% |
| Q1 2025 | 32.40% |
| Q4 2024 | -14.66% |
| Q3 2024 | -6.98% |
| Q2 2024 | 988.42% |
| Q1 2024 | -175.71% |
| Q4 2023 | -81.24% |
| Q3 2023 | -5.54% |
| Q2 2023 | 132.47% |
| Q1 2023 | -4.39% |
| Q4 2022 | -18.76% |
| Q3 2022 | 122.33% |
| Q2 2022 | -952.25% |
| Q1 2022 | 108.55% |
| Q4 2021 | -60.81% |
| Q3 2021 | -57.52% |
| Q2 2021 | 46.21% |
| Q1 2021 | 127.51% |
| Q4 2020 | 728.67% |
| Q3 2020 | -77.35% |
| Q2 2020 | -81.40% |
| Q1 2020 | 349.80% |
| Q4 2019 | 79.39% |
| Q3 2019 | -493.63% |
| Q2 2019 | 79.96% |
| Q1 2019 | -505.33% |
| Q4 2018 | -68.77% |
| Q3 2018 | 141.18% |
| Q2 2018 | -384.89% |
| Q1 2018 | -19.57% |
| Q4 2017 | 0.34% |
| Q3 2017 | 76.56% |
| Q2 2017 | 4.39% |
| Q1 2017 | -53.71% |
| Q4 2016 | 0.00% |